424B4
priced
Final prospectus
Final prospectus filed after pricing with final deal terms.
First tracked pre-IPO filing for this issuer.
Price $18.00 · 17,640,000 shares · Gross proceeds $317,520,000
Common Stock · Exchange Nasdaq Global Select Market · Ticker LYCA · Over-allotment 2,646,000 · Underwriters Jefferies, TD Cowen, Evercore ISI
Lycia Therapeutics, Inc. has filed a 424B4 prospectus supplement detailing the underwriters' option to purchase additional shares, lock-up restrictions, and stabilization activities. The underwriters, Jefferies LLC and TD Securities (USA) LLC, have a 30-day option to buy up to 2,646,000 additional shares at the public offering price. A 180-day lock-up period restricts sales of securities, with exceptions for specific transactions. Stabilization activities, including short sales and syndicate covering transactions, may influence the stock price. The filing also outlines restrictions on share sales and transfers during the lock-up period.
2026-10-23 · 0001628280-26-067048
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
First tracked pre-IPO filing for this issuer.
2026-10-22 · 9999999995-26-003321
CERT
inactive
CERT
Pre-IPO filing captured from the SEC submission timeline.
First tracked pre-IPO filing for this issuer.
2026-10-22 · 0001354457-26-001015
8-A12B
effective
Exchange Act registration
Registration filed to list the securities under the Exchange Act ahead of trading.
Follows DRS and registers the class of securities for exchange listing.
2026-10-20 · 0001628280-26-066384
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
First tracked pre-IPO filing for this issuer.
Range $16.00 to $18.00 · 14,700,000 shares · Gross proceeds $249,900,000
Common Stock · Exchange Nasdaq Global Select Market · Ticker LYCA · Over-allotment 2,205,000 · Use of proceeds working capital
Lycia Therapeutics, Inc. has amended its S-1 filing to detail underwriter provisions, including a 30-day option for underwriters to purchase up to 2,205,000 additional shares at the public offering price. The filing outlines lock-up agreements restricting share sales for 180 days post-IPO, with exceptions for specific transactions. Stabilization activities by underwriters, such as short sales and syndicate covering transactions, are disclosed to potentially influence stock prices. The document also addresses electronic distribution methods and underwriter relationships.
2026-10-20 · 0001628280-26-066381
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS/A in the pre-IPO sequence.
Common Stock · Exchange Nasdaq Global Market · Ticker LYCA
Lycia Therapeutics, Inc. filed an S-1 registration statement in October 2026, disclosing financial results through mid-2026. The company terminated its Lilly collaboration in February 2026, leading to a significant decline in collaboration revenue. A new non-exclusive license agreement with RSR in July 2025 grants rights to TSHR patents for preclinical LYTAC degrader development, requiring $12M in potential milestones. Research and development expenses decreased slightly in 2025 amid restructuring efforts, while general and administrative costs also declined. The company faces risks related to clinical trial outcomes, regulatory approvals, and dependence on collaboration revenue.
2026-10-05 · 0001628280-26-064973
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS filing.
Lycia Therapeutics, Inc. is preparing for its initial public offering (IPO) with underwriters Jefferies LLC and TD Securities (USA) LLC. The offering includes a public price for common stock, underwriting discounts, and a potential option for underwriters to purchase additional shares. The company plans to list on Nasdaq under the symbol "LYCA," contingent on approval. The filing outlines market-making intentions, liquidity risks, and restrictions on share sales during a 180-day lock-up period. Stabilization activities by underwriters may influence stock prices, and no guarantees are provided for trading market liquidity or favorable sale prices.
2026-08-27 · 0001806540-26-000005
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
Lycia Therapeutics, Inc. reported collaboration revenue of $14.9 million in 2024 and $6.7 million in 2025 from the Lilly Agreement, which terminated in February 2026. A new non-exclusive license agreement with RSR in July 2025 granted rights to TSHR patents for preclinical development, involving $0.3 million upfront fees and potential milestone payments up to $12.0 million. The company incurred restructuring charges of $1.5 million in 2025 due to workforce reductions and operational adjustments. Liquidity improved after a $75.0 million Series D financing in June 2026, but the firm remains unprofitable with an accumulated deficit of $117.6 million as of December 2025. Future revenue depends on clinical progress and potential collaborations, with significant R&D expenses anticipated.
2026-07-02 · 0001628279-26-000815